Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 235

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 235
---
,493 |

____________ Notes:- (i)The historical financial information of APx has been adjusted to give effect to the differences between GAAP and IFRS as issued by the IASB for the purposes of the unaudited pro forma combined consolidated financial information. See “ Notes to Unaudited Pro Forma Combined Consolidated Financial Information — GAAP to IFRS conversion of APx’s financial information as of June 30, 2024 and for the twelve -month period ended June 30, 2024 and the six -month period ended June 30, 2024.” (ii)Includes the liabilities disclosed by APx under “ Accrued expenses and accounts payable.” (iii)Includes the liabilities disclosed by APx under “ Convertible note payable.” See the accompanying notes to the unaudited pro forma combined consolidated financial information.

102 Notes to Unaudited Pro Forma Combined Consolidated Financial Information Description of Business Combination On March 25, 2024, APx, OmnigenicsAI and Merger Sub entered into the Business Combination Agreement. Subject to the terms and conditions of the Business Combination Agreement, at the Merger Effective Time: •each SPAC Unit issued and outstanding immediately prior to the Merger Effective Time shall be automatically separated and the holder thereof shall be deemed to hold one SPAC Class A Ordinary Share and one -halfof a SPAC Warrant; provided that no fractional SPAC Warrants shall be issued in connection with such separation such that if a holder of such SPAC Units would be entitled to receive a fractional SPAC Warrant upon such separation, the number of SPAC Warrants to be issued to such holder upon such separation will be rounded down to the nearest whole number of SPAC Warrants; •immediately following the separation of each SPAC Unit, each SPAC Class A Ordinary Share, issued and outstanding immediately prior to the Merger Effective Time shall be automatically surrendered, cancelled and cease to exist in exchange for the right to receive, upon delivery of the applicable Letter of Transmittal, one newly issued Company Share. Each SPAC Shareholder shall cease to have any other rights in and to such SPAC Ordinary Shares, except as expressly provided in the Business Combination Agreement; and •immediately following the separation of each SPAC Unit, each SPAC Warrant issued and outstanding immediately prior to the Merger Effective Time shall cease to be a warrant with respect to SPAC Ordinary Shares and be assumed by the Company and converted into a validly issued and